Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
1. VK2735 showed up to 12.2% weight loss vs 1.3% for placebo. 2. The trial demonstrated VK2735's safety and tolerability over 13 weeks. 3. 96% of VK2735 subjects achieved ≥5% weight loss compared to 10% for placebo. 4. The study's findings support VK2735's efficacy for obesity treatment. 5. Management will discuss results in today's conference call.